This suggests that ADAR can be used as a superior response marker for PD1 immunotherapy (the recommended immunotherapy strategy for patients with muscle-invasive and metastatic BLCA [23] in patients with BLCA (Figure 7E). Here, ADAR is linked to bladder transitional cell carcinoma.